logo
Beyond talking the talk: Regal Elementary staff literally walk the walk to boost attendance

Beyond talking the talk: Regal Elementary staff literally walk the walk to boost attendance

Yahoo3 days ago

May 29—During his first year as a counselor at Regal Elementary, Tony DeBari used the standard method to reach families when their kids were not in class. He called their home, which for many kids was a five-minute walk from school.
But the phone calls weren't enough to get the kids to school or build relationships with families, Debari said. Midway through last year, a thought struck him.
"After the phone calls weren't working, I was like, 'Well, let's go pick them up,' " he said, and started the school's first "walking school bus," going door to door each morning to amass a herd of students to walk to school.
The "bus" services around 40 students who live along two predetermined routes, too close to qualify for Regal's one school bus. Much like a big yellow school bus, staff and volunteers walk to each kids' address before school. Staff knock on each door with a bright, "Regal, Regal!" and wait a few beats for their pupil to emerge, usually grinning or groggy.
Each morning, two teams of staff and volunteers assume the routes, one is a longer route that crosses the four lanes of Wellesley Street; it has a crosswalk, but the flashing lights indicating a pedestrian is crossing the street are only activated by a key that staff have.
"Families were scared to cross Wellesley," DeBari said, describing foggy or dark early hours that could shroud a kid crossing a busy street in commuter traffic.
The shorter route serves students in a nearby apartment complex, which happens to be home to many refugee and immigrant families. Often, punctuality at school takes some getting used to, one of the many adjustments one makes when moving to a new country.
"A lot of it for me is taking something off the family's plate," DeBari said.
On one morning last week, a crew of three staff and three volunteers meandered through the Regal Arms apartments, a Bluetooth speaker hung on librarian Simeon Bergstedt's lanyard, playing a cover of "Three Little Birds."
He knocked on each door and waited for the kids to hop on the nonexistent bus. Wearing a foam ram head as a hat and waving blue pom poms, his presence cracks a smile from a few of his riders when they open their front door, still wiggling on their shoes or shrugging on their backpacks.
"It takes a huge pressure off families," Bergstedt said "When all you got to do is open that door and there's a reindeer hat and music playing, it makes it a lot easier to get to school on time."
DeBari started the initiative part way through his first year at the school in an effort to boost attendance in some of his most chronically absent pupils. Along the way, he saw unintended side effects like convening with families and building trust by literally meeting them where they are, he said. He saw kids grow close, building a bond "kinda like a sports team, they want to be part of it," he said.
Originally, he was the "alarm clock" for many of his students. At his knock they'd come to the door sleepily rubbing their eyes and assume the groggy march to school. But at least they'll be at school on time, he said.
Now his kids chastise him for his tardiness when he's a few moments late for pick up.
His endeavors appear to be paying off, according to Spokane Public Schools attendance data. Of current walking school bus participants who also walked last year, 88% of them increased or maintained their attendance level. A fourth of them reached what the district deems "satisfactory attendance," missing no more than 9 days of the 180-day school year.
Improving attendance has long been a goal of schools following the pandemic, when "chronic absenteeism," defined as missing 10% of the school year, or 18 days, has sharply increased and shown little signs of slowing. The proportion of chronically absent students nearly doubled around the state from 15% to 27% between the 2018-19 school year, the last full one before the pandemic, and 2023-24, the latest year with available data according to the Office of the Superintendent of Public Instruction.
In Spokane Public Schools' rates of chronic absenteeism jumped from 17% to 32% in those same years.
Joe Johnston, a professor of sociology at Gonzaga University, embeds the walking school bus in his courses, even publishing his research on the program in recent years. He's a regular face at Logan Elementary, where many of his students lead daily walks to school in an effort to naturally build relationships with the schoolkids merely with their consistent presence.
"The program, on its surface, is really all about improving attendance and timeliness to school, but the way that we try to do that is through building relationships and community," Johnston said. "And if we're successful in the building of relationships and community, the attendance part sort of just takes care of itself."
By embedding themselves into the kids' daily routine at such a "tender time" in their sleepy morning walk to school, Johnston hopes to teach not only the systems and structures they learn about in their lecture halls, but also that they have the ability to address them.
"A lot of our social problems, the way that we make progress on those is through communal and social responses to that," Johnston said. "So I think there's something about the walking school bus, even though it is just a walk in the morning, that can be a real tool for understanding how we shouldn't just be sad and down and depressed; we actually got to get up and keep on doing stuff and keep on engaging."
DeBari noted anecdotal observations in his walking school bus riders' attendance, having improved "big time," he said, some of his kids even trying to come to school when they're sick and contagious. Seeing them "take ownership" of their punctuality, he said, is what drives him to continue his 7:30 a.m. marches around the neighborhood.
"Rain, shine, snow, we go," he said is the bus motto.
"You can't miss a day for those families, they're depending on you."
Elena Perry's work is funded in part by members of the Spokane community via the Community Journalism and Civic Engagement Fund. This story can be republished by other organizations for free under a Creative Commons license. For more information on this, please contact our newspaper's managing editor.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Beyond talking the talk: Regal Elementary staff literally walk the walk to boost attendance
Beyond talking the talk: Regal Elementary staff literally walk the walk to boost attendance

Yahoo

time3 days ago

  • Yahoo

Beyond talking the talk: Regal Elementary staff literally walk the walk to boost attendance

May 29—During his first year as a counselor at Regal Elementary, Tony DeBari used the standard method to reach families when their kids were not in class. He called their home, which for many kids was a five-minute walk from school. But the phone calls weren't enough to get the kids to school or build relationships with families, Debari said. Midway through last year, a thought struck him. "After the phone calls weren't working, I was like, 'Well, let's go pick them up,' " he said, and started the school's first "walking school bus," going door to door each morning to amass a herd of students to walk to school. The "bus" services around 40 students who live along two predetermined routes, too close to qualify for Regal's one school bus. Much like a big yellow school bus, staff and volunteers walk to each kids' address before school. Staff knock on each door with a bright, "Regal, Regal!" and wait a few beats for their pupil to emerge, usually grinning or groggy. Each morning, two teams of staff and volunteers assume the routes, one is a longer route that crosses the four lanes of Wellesley Street; it has a crosswalk, but the flashing lights indicating a pedestrian is crossing the street are only activated by a key that staff have. "Families were scared to cross Wellesley," DeBari said, describing foggy or dark early hours that could shroud a kid crossing a busy street in commuter traffic. The shorter route serves students in a nearby apartment complex, which happens to be home to many refugee and immigrant families. Often, punctuality at school takes some getting used to, one of the many adjustments one makes when moving to a new country. "A lot of it for me is taking something off the family's plate," DeBari said. On one morning last week, a crew of three staff and three volunteers meandered through the Regal Arms apartments, a Bluetooth speaker hung on librarian Simeon Bergstedt's lanyard, playing a cover of "Three Little Birds." He knocked on each door and waited for the kids to hop on the nonexistent bus. Wearing a foam ram head as a hat and waving blue pom poms, his presence cracks a smile from a few of his riders when they open their front door, still wiggling on their shoes or shrugging on their backpacks. "It takes a huge pressure off families," Bergstedt said "When all you got to do is open that door and there's a reindeer hat and music playing, it makes it a lot easier to get to school on time." DeBari started the initiative part way through his first year at the school in an effort to boost attendance in some of his most chronically absent pupils. Along the way, he saw unintended side effects like convening with families and building trust by literally meeting them where they are, he said. He saw kids grow close, building a bond "kinda like a sports team, they want to be part of it," he said. Originally, he was the "alarm clock" for many of his students. At his knock they'd come to the door sleepily rubbing their eyes and assume the groggy march to school. But at least they'll be at school on time, he said. Now his kids chastise him for his tardiness when he's a few moments late for pick up. His endeavors appear to be paying off, according to Spokane Public Schools attendance data. Of current walking school bus participants who also walked last year, 88% of them increased or maintained their attendance level. A fourth of them reached what the district deems "satisfactory attendance," missing no more than 9 days of the 180-day school year. Improving attendance has long been a goal of schools following the pandemic, when "chronic absenteeism," defined as missing 10% of the school year, or 18 days, has sharply increased and shown little signs of slowing. The proportion of chronically absent students nearly doubled around the state from 15% to 27% between the 2018-19 school year, the last full one before the pandemic, and 2023-24, the latest year with available data according to the Office of the Superintendent of Public Instruction. In Spokane Public Schools' rates of chronic absenteeism jumped from 17% to 32% in those same years. Joe Johnston, a professor of sociology at Gonzaga University, embeds the walking school bus in his courses, even publishing his research on the program in recent years. He's a regular face at Logan Elementary, where many of his students lead daily walks to school in an effort to naturally build relationships with the schoolkids merely with their consistent presence. "The program, on its surface, is really all about improving attendance and timeliness to school, but the way that we try to do that is through building relationships and community," Johnston said. "And if we're successful in the building of relationships and community, the attendance part sort of just takes care of itself." By embedding themselves into the kids' daily routine at such a "tender time" in their sleepy morning walk to school, Johnston hopes to teach not only the systems and structures they learn about in their lecture halls, but also that they have the ability to address them. "A lot of our social problems, the way that we make progress on those is through communal and social responses to that," Johnston said. "So I think there's something about the walking school bus, even though it is just a walk in the morning, that can be a real tool for understanding how we shouldn't just be sad and down and depressed; we actually got to get up and keep on doing stuff and keep on engaging." DeBari noted anecdotal observations in his walking school bus riders' attendance, having improved "big time," he said, some of his kids even trying to come to school when they're sick and contagious. Seeing them "take ownership" of their punctuality, he said, is what drives him to continue his 7:30 a.m. marches around the neighborhood. "Rain, shine, snow, we go," he said is the bus motto. "You can't miss a day for those families, they're depending on you." Elena Perry's work is funded in part by members of the Spokane community via the Community Journalism and Civic Engagement Fund. This story can be republished by other organizations for free under a Creative Commons license. For more information on this, please contact our newspaper's managing editor.

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Associated Press

time23-01-2025

  • Associated Press

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification – - Based on a Review of Unblinded Data, the IDMC Confirmed that GPS Exceeded the Predetermined Futility Criteria, Noted no Safety Concerns and Commended SELLAS for its Operational Excellence and Study Data Integrity - - Fewer than 50% of Enrolled Patients Confirmed Deceased After the Median Follow-Up of 13.5 Months, Indicating a Median Survival of Over 13.5 Months in the Trial vs. Historical Median Survival of 6 Months for Conventional Therapy, as Reported in Similar Phase 2 Study - - 80% of Randomly Selected REGAL GPS Patients Showed a Specific T-Cell Immune Response, Surpassing the Results From the Previous Phase 2 Study - - Next and Final Analysis Planned Upon Reaching 80 Events - NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS'' or the 'Company'), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Independent Data Monitoring Committee (IDMC) has completed pre-specified interim analysis of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). Following this interim analysis triggered by 60 events (deaths) in the study population, the IDMC has recommended that the trial continue without modifications. The interim futility, efficacy, and safety analysis is designed to assess whether the therapy is safe, demonstrates potential efficacy, and merits continuation. The IDMC's review of the interim data supports the continuation of the study according to its original protocol. Based on this positive evaluation, GPS has shown preliminary signals of effectiveness, allowing the trial to advance toward completion. The next and final analysis will be conducted once 80 events (deaths) are reached, further determining the potential of GPS in addressing the needs of AML patients. SELLAS anticipates that 80 events will be reached this year. 'I am thrilled by the positive outcome of the interim analysis of our Phase 3 REGAL trial, marking the successful achievement of the most significant milestone for our GPS program to date. The IDMC's recommendation to support the continued advancement of GPS in our REGAL trial brings us one step closer towards potential approval for the treatment of AML,' said Angelos Stergiou, MD, ScD hc, President and Chief Executive Officer of SELLAS. 'Based on all available data, we believe that GPS could become a transformative treatment option for AML, offering hope to patients with limited choices, especially those with relapsed or refractory disease. We are optimistic about the IDMC's recommendation to continue the study without modifications, and diligently preparing for the Biologics License Application (BLA). Importantly, the REGAL trial provides a clear and straightforward path toward seeking regulatory approval for patients with AML in their second complete remission. We look forward to completing the trial with the final analysis to be conducted once 80 events are reached.' The Company is blinded to the trial outcomes, following regulations that safeguard study integrity. However, select blinded data has been presented, revealing that fewer than half of the enrolled patients have been confirmed deceased approximately 10 months after completion of enrollment, and an approximate median follow-up of 13.5 months (range 1 month to more than 3 years). This suggested a pooled median survival exceeding 12 months, compared to the expected survival of approximately 6 months in a similar patient population (patients in second complete remission who did not receive a transplant after the second remission). Separately, a blinded analysis of early immune response in a randomly selected sample of patients receiving GPS showed GPS-specific immune response in 80% of patients. These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 months for patients on standard of care therapy and a GPS-specific immune response of 64%. These promising data have encouraged the Company to continue preparations for the preclinical, clinical, manufacturing, and quality assurance components of the BLA regulatory submission in anticipation of final clinical data. No drug has yet been approved specifically for maintenance of remission in AML patients in CR2, further emphasizing the significance of this development. 'The interim results represent a major step forward in the treatment of AML, offering hope for patients in remission,' said Dr. Yair Levy, Director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical Center. 'I am very hopeful that we will see a new standard of care in treating AML patients based on the outcomes we have observed in previous GPS trials.' In his comments during a recent webinar on January 8, Dr. Levy also stated, that he believes 'that if approved, GPS would be highly accepted by the medical community and patients, and would become a standard-of-care in this high unmet need population. In addition to efficacy, this is also an extremely well-tolerated therapy. GPS efficacy does not come at the cost of quality of life. GPS has been shown to be very safe, with minimal side effects … This is particularly important, given that up to 60% of patients who receive standard therapies experience severe side effects, usually in the form of decreased white blood cell count, platelet count, and red blood cell count. These low counts, or cytopenias, often necessitate frequent hospitalizations or other interventions.' REGAL is a Phase 3 open-label registrational clinical trial for GPS in AML patients who have achieved complete remission following second-line salvage therapy (CR2 patients). The primary endpoint is overall survival. The IDMC is an independent group of medical, scientific, and biostatistics experts who are responsible for reviewing and evaluating patient safety and efficacy data for REGAL, and for monitoring quality and overall conduct to ensure the validity, scientific and clinical merits of the study. The IDMC charter provides for periodic reviews of safety, efficacy, and futility in addition to the interim and final analyses. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan,' 'expect,' 'anticipate,' 'may,' 'might,' 'will,' 'should,' 'project,' 'believe,' 'estimate,' 'predict,' 'potential,' 'intend,' or 'continue' and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 28, 2024 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made. Investor Contact Bruce Mackle Managing Director LifeSci Advisors, LLC Media Contact Michael Fitzhugh

SELLAS Announces Key Business Objectives for 2025
SELLAS Announces Key Business Objectives for 2025

Associated Press

time08-01-2025

  • Associated Press

SELLAS Announces Key Business Objectives for 2025

- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expected in 1H 2025 - - Approval of 'tambiciclib' as Recommended International Nonproprietary Name for SLS009 - - Applied for Non-Dilutive Grant Funding to Expand SLS009 Development Into Frontline Setting in AML - - Developing SLS009 Pediatric Programs in Hematological and Potentially Other Malignancies - - Company to Host Corporate Update Webinar Today, January 8, 2025, at 9:00 am ET - NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS'' or the 'Company'), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a webinar at 9:00 am ET. 'We believe that 2025 will be a pivotal year for SELLAS as we continue to advance our clinical stage portfolio of novel therapeutics for hematologic malignancies,' said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. 'We aim to build on the excellent progress achieved in 2024 and look forward to several, potentially transformative clinical milestones. Specifically, we anticipate full topline dataset from our Phase 2 trial of SLS009 in acute myeloid leukemia (AML) patients resistant to venetoclax combination therapies and FDA regulatory feedback around our SLS009 study, as well as the interim analysis from Phase 3 REGAL being conducted by the Independent Data Monitoring Committee (IDMC). Based on the results of this analysis, the IDMC will provide their recommendation in January to either stop the trial early for efficacy, stop for futility, or continue the study without modification. If the recommendation is to continue, the next and final analysis will take place upon reaching a total of 80 events, as predefined in the study protocol.' Dr. Stergiou continued, 'We are also pleased that the potential of both of our assets has been recognized by the regulatory agencies. During 2024, GPS was granted FDA Rare Pediatric Disease Designation for pediatric AML and SLS009 was granted RPDD for pediatric AML and pediatric acute lymphoblastic leukemia, FDA Fast Track Designation for AML, and EMA orphan drug designation for AML and peripheral T-cell lymphoma. These designations underscore the significant unmet medical needs which our therapies aim to address and reinforce the confidence of regulatory authorities in our innovative approach to treating a broad range of cancer indications.' Expected Milestones in 2025: Galinpepimut-S (GPS): Wilms Tumor-1 (WT1) targeting immunotherapeutic Phase 3 REGAL study in AML: The interim analysis from the ongoing REGAL global Phase 3 registrational clinical trial of GPS in patients with AML who have achieved complete remission following second-line salvage therapy (CR2 patients) is expected in January 2025. Based on the results of this analysis, the IDMC will provide recommendations to either stop the trial early for efficacy, stop for futility, or continue the study without modification. If the recommendation is to continue without modification, the next and final analysis will take place upon reaching a total of 80 events, as predefined in the study protocol. SLS009: highly selective CDK9 inhibitor Phase 2 clinical trial in AML: Full topline data from expansion cohorts which include AML-MRC patients with ASXL1 mutation (cohort 4) and mutations and cytogenic changes other than ASXL1 (cohort 5) are expected in 1H 2025. FDA feedback on regulatory path for r/r AML study expected in 1H 2025. 2024 Key Achievements: Galinpepimut-S (GPS): Wilms Tumor-1 (WT1) targeting immunotherapeutic Phase 3 REGAL study of GPS in AML reached pre-specified threshold of 60 events (deaths) initiating the interim analysis being conducted by the Independent Data Monitoring Committee (IDMC). SLS009: highly selective CDK9 inhibitor The World Health Organization (WHO) has approved ' tambiciclib' as the recommended International Nonproprietary Name (INN) for SLS009 Reported positive data from the ongoing Phase 2 trial of SLS009 in r/r AML in Q4 2024. The median overall survival (mOS) has not been reached but exceeds 7.7 months at the latest follow-up, marking a significant milestone for patients in this setting, where the expected mOS is historically around 2.5 months. In expansion cohorts in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation and mutations and cytogenic changes other than ASXL1, the ORR was 56% in 9 evaluable for efficacy patients, exceeding pre-specified target response rate of 33%. Presented data from Phase 2a trial of SLS009 in r/r AML at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024. Treatment with SLS009 in combination with azacitidine and venetoclax was well tolerated and led to a 50% response rate in the selected optimal dose level of 30 mg twice a week. Clinical activity was even higher in patients with AML-MRC and in particular, those with ASXL1 mutations, suggesting that this subset of patients may exhibit preferential sensitivity to SLS009. In the safety dose of 45mg once a week, SLS009 showed a mOS of 5.5 months. Completed enrollment in Phase 2a Trial of SLS009 in r/r AML: 30 patients relapsed after or refractory to venetoclax-based regiments were enrolled ahead of schedule in 5 centers across the US. Except for one, all patients in the Phase 2a trial had adverse risk AML (97%) and were treated with continued venetoclax–azacytidine combination therapy after having failed it or similar venetoclax-based combinations, often more than once. Opened enrollment in additional Phase 2 cohorts in venetoclax combinations in r/r AML. Development of SLS009 continues with the opening of two new cohorts - AML MRC with ASXL1 mutations and AML with myelodysplasia related changes other than ASXL1 mutations. These new cohorts are also open for enrollment of certain pediatric patients. Announced positive preclinical data indicating ASXL1 mutations as predictors of response to SLS009 in solid cancers. Published in Oncotarget, revealing the underlying mechanisms of action behind the anti-proliferative effects of SLS009 in various hematologic malignancies. Continued National Cancer Institute (NCI) Pediatric Preclinical in Vivo Testing (PIVOT) Program in pediatric tumor. Regulatory: Received multiple regulatory designations: for GPS: FDA Rare Pediatric Disease Designation (RPDD) for pediatric AML, for SLS009: RPDD for pediatric AML, pediatric acute lymphoblastic leukemia (ALL), FDA Fast Track Designation for AML, and EMA orphan drug designation (ODD) for AML and peripheral T-cell lymphoma (PTCL). To access the webinar, please use the following information: Date: Wednesday, January 8, 2025 Time: 9:00 a.m. Eastern Time Webcast: 2025 Business Outlook About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan,' 'expect,' 'anticipate,' 'may,' 'might,' 'will,' 'should,' 'project,' 'believe,' 'estimate,' 'predict,' 'potential,' 'intend,' or 'continue' and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 28, 2024 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made. Investor Contact Bruce Mackle Managing Director Media Contact Michael Fitzhugh

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store